Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,991 result(s) found for: vaccine. Displaying page 61 of 100.
    «« First « Previous 57  58  59  60  61  62  63  64  65  Next» Last»»
    EudraCT Number: 2011-004449-42 Sponsor Protocol Number: A3L24 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur S.A
    Full Title: Multi-center, randomized, observer blinded, Phase III trial in 1,376 infants, using Infanrix hexa™ as the control vaccine. Four-arm trial with subjects randomly allocated to receive 1 of 3 lots of ...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005013-23 Sponsor Protocol Number: M37P2E1 Start Date*: 2014-11-25
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III Open Label, Multi-Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX®
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001073-29 Sponsor Protocol Number: FLD-VAT-2007-01 Start Date*: 2008-09-19
    Sponsor Name:Fernando Lago Deibe
    Full Title: Ensayo clínico prospectivo, en fase IV, controlado, aleatorizado, doble ciego y en grupos paralelos para evaluar la efectividad y seguridad de la vacunación antitetánica en pacientes en tratamiento...
    Medical condition: Comparación de la administración intramuscular y subcutánea de la vacuna Tétanos-Difteria Adultos en pacientes tratados con anticoagulantes orales. Comparison of the intramuscular and subcutaneo...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053468 Anticoagulant therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015588-15 Sponsor Protocol Number: IC51-323 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005337-45 Sponsor Protocol Number: PNA19 Start Date*: 2015-12-07
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed with Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) ...
    Medical condition: Healthy volunteers: prevention of invasive disease caused by S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F and prevention of otitis media caused by S pneumoniae serotypes 4, 6B, 9V, 14, ...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000880-34 Sponsor Protocol Number: 207489 Start Date*: 2017-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002111-22 Sponsor Protocol Number: BCG/COVID-19/UR/04/2020 Start Date*: 2020-06-26
    Sponsor Name:University of Rzeszów
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in ...
    Medical condition: not applicable
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004650-25 Sponsor Protocol Number: 110521 Start Date*: 2015-05-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-dose pr...
    Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants against Streptococcus pneumonia, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and polio diseases)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    18.0 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    18.0 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    18.0 100000004862 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004523-36 Sponsor Protocol Number: CVac-Tü3 Start Date*: 2019-04-17
    Sponsor Name:University Clinics Tübingen
    Full Title: Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany
    Medical condition: Immunization of healthy volunteers against P. falciparum infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001545-20 Sponsor Protocol Number: mRNA-1647-P104 Start Date*: 2024-05-09
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age...
    Medical condition: Cytomegalovirus infection
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-002976-41 Sponsor Protocol Number: ZonMW522004008 Start Date*: 2019-07-09
    Sponsor Name:RIVM
    Full Title: ‘Premature infants and maternal pertussis immunization. Is second trimester vaccination beneficial?’
    Medical condition: women in their first trimester of pregnancy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005564-21 Sponsor Protocol Number: SIRAVA Start Date*: 2021-12-28
    Sponsor Name:Leiden University Medical Center
    Full Title: Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis.
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001301-28 Sponsor Protocol Number: S206.3.012 Start Date*: 2006-05-19
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subject...
    Medical condition: Prophylaxis of influenza in adults and the elderly, especially in those who run an increased risk of associated complications.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002448-21 Sponsor Protocol Number: ACTIVATEII Start Date*: 2020-05-26
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036897 Prophylactic vaccination LLT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001095-21 Sponsor Protocol Number: A5I16 Start Date*: 2016-04-19
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed),...
    Medical condition: Pertussis, adsorbed diphtheria and tetanus toxoids, inactivated poliomyelitis and polysaccharide of H. influenza type b bound to tetanus toxoid
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001038-28 Sponsor Protocol Number: S201.3.127 Start Date*: 2008-05-27
    Sponsor Name:Solvay Biologicals BV
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2008/2009. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult S...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010900-27 Sponsor Protocol Number: S201.3.128 Start Date*: 2009-05-08
    Sponsor Name:Solvay Biologicals BV
    Full Title: Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult s...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018350-13 Sponsor Protocol Number: S201.3.130 Start Date*: 2010-05-12
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult S...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001305-25 Sponsor Protocol Number: 114249 Start Date*: 2015-06-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, observer-blinded, multi-center, controlled study to assess the safety and immunogenicity of one dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus toxoid co...
    Medical condition: Healthy volunteers (for one dose primary immunization against meningococcal serogroups A, C, W-135 and Y diseases in healthy subjects aged 10 through 25 years)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004848 10070124 Neisseria meningitidis test positive LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 57  58  59  60  61  62  63  64  65  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:29:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA